Publication with PolarCap® System in a scientific journal ("Concussion")
The publication entitled "Selective head-neck cooling after concussion shortens return-to-play in ice hockey players" has now been published by Future Medicine in their journal Concussion. The scientific publication is an analysis of data from the study with Swedish Hockey League (SHL) and HockeyAllsvenskan, where a total of 81 cases of concussions are included. The result shows significant positive effects in the form of shortened Return-To-Play (median 7 days for intervention versus 12.5 days for control) and reduced proportion of long-term absence (7% in intervention versus 25% in control) for players cooled with PolarCap® System.
The clinical result of the study opens up the cooling market for concussion treatment, as this is the largest study population in sports-related concussions showing statistically benefits of cooling in treating concussions with the head and neck cooling technology by PolarCap® System. The incidence of sports-related concussions is a significant national health concern and there is growing evidence that repetitive mTBI (mild Traumatic Brain Injury) can cause long-term changes in brain structure and function, not least in ice hockey, and available treatment options are limited.
PolarCools CEO Erik Andersson comments:
- We know that the market at an early stage is dependent on medical acceptance. A publication is a proof that the data presented is scientifically relevant. For PolarCool, this means that we have an even stronger tool in our market processing where clinical evidence for treatment with PolarCap® System is a central part. The publication also gives increased weight to the data received after this study, which strengthened the statistical significance regarding the positive effects demonstrated in this study. In several of our conversations with medical representatives, a publication has been requested, which we now have.
This information is information that PolarCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on April 16th, 2021.
For more information
Erik Andersson – CEO PolarCool AB (publ)
+46 - 738 60 57 00
E-mail: erik.andersson@polarcool.se
About PolarCool AB (publ)
PolarCool AB (publ) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.